Beruflich Dokumente
Kultur Dokumente
INSTRUCTIONS: Please submit 1 hard copy of this form, together with the appropriate supporting documentation.
TO THE PRINCIPAL INVESTIGATOR Please indicate in the space provided below whether or not the specified assessment point is
(PI): addressed by your study protocol. To facilitate the evaluation of the assessment point,
indicate the page and paragraph where this information can be found or “NA” if not
applicable.
TO THE PRIMARY REVIEWER: Please evaluate how the assessment points outlined below have been appropriately
addressed by the study protocol, as applicable by confirming the submitted information and
putting your comments in the space provided. Indicate your conclusions under
“RECOMMENDED ACTION” and sign on space provided.
SEC.
B STUDY PROTOCOL ASSESSMENT FORM FOR PROTOCOL NO. _________________
Page
where Reviewer: _________________________
ASSESSMENT POINTS found c/o
Project N Unable Explanation if no or unable to assess or
Leader Yes
o to assess indicate “NA” if not applicable
B1 1. SCIENTIFIC VALIDITY
sufficiently
knowledgeable/trained to conduct
the proposed study based on
his/her/their dated and signed
Talamban Campus, Nasipit, Talamban, Cebu City, Philippines 6000
Phone: +63 (32) 2300100 loc 204 and 2547742 Email: rec@usc.edu.ph Website: www.usc.edu.ph
Research Ethics Committee
Reviewer: _________________________
Page
ASSESSMENT POINTS where
found c/o
appropriate?
2.6. Does the selection and
recruitment of participants p. 17 para 3
comply with the ethical demands
of equity?
2.7. Is the duration of human
participants’ involvement in the p. 18 par 1
study reasonable?
2.8. Does the study involve individuals
who are vulnerable, i.e. those
whose pertinent circumstances p. 19 par 3
will likely impair their capacity to
give free, prior and informed
consent?
2.9. Are appropriate mechanisms in
p. 19 para
place to protect the potential 3, Appendix
vulnerable participants, e.g. B
assent form for children?
2.10. Are probable risks/harm to
the human participants as result
of participation in the study p. 19 par 3,
Appendix B
clearly identified, i.e. physical,
psychological, social, economic,
legal?
2.11. In order to adequately
address the risk/benefit balance,
does the protocol provide p. 19 par 3,
means/mechanisms that Appendix B
sufficiently mitigate the
risks/probable harm to the
human participants?
2.12. Is the informed consent
procedure/form adequate and
culturally appropriate, e.g. p. 41
(back-)translation is appended?
Indicate “NA” if not applicable.
B3 3. DATA PROTECTION PLAN
3.1. Does the study involve
personal/sensitive data collection p. 19 par 2
and/or processing?
Reviewer: _________________________
Page
ASSESSMENT POINTS where
found c/o
accessed?
3.10. Does the study clearly state
how and when collected data will p. 19 par 2
be (ir)reversibly
disposed/destroyed?
RECOMMENDED ACTION:
EXEMPT FROM REVIEW
APPROVED
MINOR MODIFICATIONS REQUIRED
MAJOR MODIFICATIONS REQUIRED
DISAPPROVED
JUSTIFICATION:
PRIMARY REVIEWER:
_________________________ ______________
Signature over printed name Date: <dd/mm/yyyy>
PANEL SECRETARY:
________________________ ______________
Signature over printed name Date: <dd/mm/yyyy>
PANEL CHAIR:
________________________ ______________
Signature over printed name Date: <dd/mm/yyyy>